RecruitMe Clinical Trial

A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
A study for patients with advanced melanoma, solid tumors or lymphoma using study drug Pembrolizumab
Sponsor:Merck Sharp & Dohme Corp.
Enrolling:Male and Female Patients
Maximum Age:17 years old
IRB Number:AAAQ7819
U.S. Government ID:NCT02332668
Contact: Rebecca Zylber, NP: 212-305-5808 / rjv2107@cumc.columbia.edu
Additional Study Information:

This study will enroll children from 6 months to 17 years old that have solid tumor cancers or lymphoma (cancer of the cells in the lymph nodes, part of the body's immune system). The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475) as well as look for the highest dose of pembrolizumab that can be given safely without serious side effects. This study will also attempt to find out how pembrolizumab is absorbed and broken down and determine how treatment with pembrolizumab may benefit children with cancer.

Do You Qualify?
Has your child been diagnosed with any of the above mentioned cancers?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Rebecca Zylber, NP
Email: rjv2107@cumc.columbia.edu
Phone: 212-305-5808